HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy (NCT06126640) | Jiangsu HengRui Medicine Co., Ltd. | 2023-11-20 |
Track HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy automatically
Every clearance here is in the API, with alerts when new ones post.